Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens

@inproceedings{Kono2012MulticenterPI,
  title={Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens},
  author={Koji Kono and Hisae Iinuma and Yasunori Akutsu and Hiroaki Tanaka and Naoko Hayashi and Yasuto Uchikado and Tsuyoshi Noguchi and Hideki Fujii and Kota Okinaka and Ryoji Fukushima and Hisahiro Matsubara and Masaichi Ohira and Hideo Baba and Shoji Natsugoe and Seigou Kitano and Kazuyoshi Takeda and Koji Yoshida and Takuya Tsunoda and Yusuke Nakamura},
  booktitle={Journal of Translational Medicine},
  year={2012}
}
Since a phase I clinical trial using three HLA-A24-binding peptides from TTK protein kinase (TTK), lymphocyte antigen-6 complex locus K (LY6K), and insulin-like growth factor-II mRNA binding protein-3 (IMP3) had been shown to be promising for esophageal squamous cell carcinoma (ESCC), we further performed a multicenter, non-randomized phase II clinical… CONTINUE READING